Management of immune checkpoint inhibitor‐related dermatologic adverse events

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy‐related adverse events. The most common symptoms are maculop...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Xiaoyan, He, Chunxia, Zhang, Li, Liu, Xiaowei, Li, Yue, Wang, Hanping, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997012/
https://www.ncbi.nlm.nih.gov/pubmed/31814310
http://dx.doi.org/10.1111/1759-7714.13275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997012/
https://www.ncbi.nlm.nih.gov/pubmed/31814310
http://dx.doi.org/10.1111/1759-7714.13275

Ejemplares similares